Treatment of Ulcerative Colitis: Moving Toward a New Array of Therapeutics

Sandra Quezada, MD


May 05, 2022

While reminiscing on time spent in medical school and residency, Sandra Quezada, MD, recalls the shifting character of discussion with colleagues and patients over the years regarding options in treatment for ulcerative colitis (UC), as therapeutics expanded over the past two decades from a triad of steroids, infliximab, and surgery to a widening array of biologics and small-molecule treatments.

This evolution has given the UC patient more options, allowing the use of a succession of agents to correct for cases of medication resistance, minimize side effects, and, perhaps most significant, reduce the role of invasive surgery.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.